Back to Search
Start Over
Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma.
- Source :
- Neuro-Oncology; Jan2021, Vol. 23 Issue 1, p122-133, 12p
- Publication Year :
- 2021
Details
- Language :
- English
- ISSN :
- 15228517
- Volume :
- 23
- Issue :
- 1
- Database :
- Complementary Index
- Journal :
- Neuro-Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 148453703
- Full Text :
- https://doi.org/10.1093/neuonc/noaa145